Scientists have identified several promising biomarkers and immune-related signatures across cancer types. Quest Diagnostics obtained FDA breakthrough designation for a colorectal cancer test detecting minimal residual disease via circulating tumor DNA. In gastric cancers, defined immune profiles predict responses to PD-1 blockade and chemotherapy. Researchers also unveiled novel biomarkers for thyroid and glioma prognosis, paving the way toward better-targeted therapies and personalized interventions.